UPCC 11417: A Phase 3 Multicenter Randomized Open-Label

Build status - In Progress

Recruiting

99 years or below

All

Phase 3

9 participants needed

1 Location

Brief description of study

Request for collaborative review: WIRB serving as IRB of record.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Acute Myeloid Leukemia
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 827342

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

View email

Phone

View phone

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center

UPCC 11417: A Phase 3 Multicenter Randomized Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Previously Treated Acute Myeloid Leukemia

Brief description of study

Eligibility of study

Find a site

Interested in the study